Airway epithelial cell membrane stabilization

"Airway epithelial cell membrane stabilization" is not a specific molecule or receptor but rather describes a physiological process critical for maintaining lung health. The airway epithelium forms a protective barrier that prevents entry of pathogens and harmful substances while regulating fluid balance. This stability is maintained by intercellular junctions—tight junctions and adherens junctions—that connect cells together and link them to the cytoskeleton, preserving both structure and function[2][4]. Mechanical stresses from processes like airway collapse/reopening during ventilation can disrupt this membrane; pulmonary surfactants help stabilize it by reducing surface tension, thus protecting against direct trauma to the cells[1]. Loss or dysfunction in this stabilizing mechanism contributes to diseases such as asthma, chronic obstructive pulmonary disease (COPD), infections, and ventilator-induced lung injury through increased permeability and impaired immune regulation[3][4]. While drugs like exogenous surfactants are used therapeutically in some contexts (notably neonatal respiratory distress), "airway epithelial cell membrane stabilization" itself is not a discrete drug target but an important therapeutic goal. Because "Airway epithelial cell membrane stabilization" refers to a process rather than a single molecular entity or canonical drug target class such as receptor/enzyme/transporter/etc., it should be flagged as incorrect for structured target databases.

Surfactants stabilize the airway epithelial cell membrane by reducing surface tension, thereby preventing mechanical stress-induced plasma membrane disruptions during airway reopening events[1].